PhotoPharmics Phase 2 Parkinson’s Disease

April 16, 2026

PhotoPharmics will be attending the American Academy of Neurology Annual Meeting (AAN) in Chicago, April 18-22. PhotoPharmics’ pivotal Phase 3 Light for Parkinson’s Disease clinical trial is in its final weeks, and topline results will likely be shared at the World Parkinson Congress in late May. This fully remote, randomized, double-blind, placebo-controlled study is evaluating Celeste®, an investigational photo-neuromodulation device, in individuals living with Parkinson’s disease.

If you’ll be at AAN, drop by the PhotoPharmics Booth, #3614.